Study outcomes and endpoints: * Primary outcome: to assess clinical characteristics of infants with confirmed COVID-19 infection at birth and to evaluate long-term respiratory consequences of neonatal COVID-19 infection. * Secondary outcome: to evaluate the prevalence and natural history of lung function impairment among infants with confirmed COVID-19 compared to infants with no history of COVID-19. To this end, infants will undergo pulmonary function testing (PFT) with the Exhalyzer D device (Eco Medics, Switzerland).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical respiratory consequences of neonatal COVID-19 infection
Timeframe: 6 months of life
Clinical respiratory consequences of neonatal COVID-19 infection (i.e. wheezing)
Timeframe: 12 months of life